Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Felner

Showing results (181-190 of 189) with videos related to

Pageof 19
Sort By:
You have reached the last page of results.This site can display upto 189 results.
The New England Journal of Medicine|June 3, 2024
Phase 3 Trial of Crinecerfont in Pediatric Congenital Adrenal HyperplasiaKyriakie Sarafoglou, Mimi S Kim, Maya Lodish, et al.
The Journal of Clinical Endocrinology and Metabolism|January 13, 2023
Diazoxide Choline Extended-Release Tablet in People With Prader-Willi Syndrome: A Double-Blind, Placebo-Controlled TrialJennifer L Miller, Evelien Gevers, Nicola Bridges, et al.
The Lancet. Diabetes & Endocrinology|July 2, 2021
Imatinib therapy for patients with recent-onset type 1 diabetes: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trialStephen E Gitelman, Brian N Bundy, Ele Ferrannini, et al.
Obesity (Silver Spring, Md.)|November 3, 2023
Diazoxide choline extended-release tablet in people with Prader-Willi syndrome: results from long-term open-label studyJennifer L Miller, Evelien Gevers, Nicola Bridges, et al.
The Journal of Clinical Endocrinology and Metabolism|January 3, 2026
Diazoxide Choline Extended-Release Tablets in Prader-Willi Syndrome: A Randomized, Double-Blind, Withdrawal Period StudyJennifer L Miller, Nicola Bridges, Eric I Felner, et al.
The Lancet. Diabetes & Endocrinology|March 14, 2014
Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trialMark R Rigby, Linda A DiMeglio, Marc S Rendell, et al.
The Journal of Clinical Investigation|July 21, 2015
Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patientsMark R Rigby, Kristina M Harris, Ashley Pinckney, et al.
Cancer Discovery|November 12, 2020
Lower Airway Dysbiosis Affects Lung Cancer ProgressionJun-Chieh J Tsay, Benjamin G Wu, Imran Sulaiman, et al.
The New England Journal of Medicine|September 28, 2022
Multicenter, Randomized Trial of a Bionic Pancreas in Type 1 Diabetes, Steven J Russell, Roy W Beck, et al.
Pageof 19

Showing results (181-190 of 189) with videos related to

Sort By:
Pageof 19
You have reached the last page of results.This site can display upto 189 results.
The New England Journal of Medicine|June 3, 2024
Phase 3 Trial of Crinecerfont in Pediatric Congenital Adrenal HyperplasiaKyriakie Sarafoglou, Mimi S Kim, Maya Lodish, et al.
The Journal of Clinical Endocrinology and Metabolism|January 13, 2023
Diazoxide Choline Extended-Release Tablet in People With Prader-Willi Syndrome: A Double-Blind, Placebo-Controlled TrialJennifer L Miller, Evelien Gevers, Nicola Bridges, et al.
The Lancet. Diabetes & Endocrinology|July 2, 2021
Imatinib therapy for patients with recent-onset type 1 diabetes: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trialStephen E Gitelman, Brian N Bundy, Ele Ferrannini, et al.
Obesity (Silver Spring, Md.)|November 3, 2023
Diazoxide choline extended-release tablet in people with Prader-Willi syndrome: results from long-term open-label studyJennifer L Miller, Evelien Gevers, Nicola Bridges, et al.
The Journal of Clinical Endocrinology and Metabolism|January 3, 2026
Diazoxide Choline Extended-Release Tablets in Prader-Willi Syndrome: A Randomized, Double-Blind, Withdrawal Period StudyJennifer L Miller, Nicola Bridges, Eric I Felner, et al.
The Lancet. Diabetes & Endocrinology|March 14, 2014
Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trialMark R Rigby, Linda A DiMeglio, Marc S Rendell, et al.
The Journal of Clinical Investigation|July 21, 2015
Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patientsMark R Rigby, Kristina M Harris, Ashley Pinckney, et al.
Cancer Discovery|November 12, 2020
Lower Airway Dysbiosis Affects Lung Cancer ProgressionJun-Chieh J Tsay, Benjamin G Wu, Imran Sulaiman, et al.
The New England Journal of Medicine|September 28, 2022
Multicenter, Randomized Trial of a Bionic Pancreas in Type 1 Diabetes, Steven J Russell, Roy W Beck, et al.
Pageof 19